Myricx Bio is developing small molecule inhibitors of cMyc, a protein that is deregulated in over 70% of all human cancers. The company has strategic partnerships with Australia’s leading integrated cancer centre, the Peter MacCallum Cancer Centre, and Australia’s premier government research organisation, CSIRO.
Myricx Bio is based in Melbourne, Australia and conducts its research and discovery activities through service providers and research collaborators in Europe, UK, USA and Australia.
https://myricxbio.com/
Myricx Bio is based in Melbourne, Australia and conducts its research and discovery activities through service providers and research collaborators in Europe, UK, USA and Australia.
https://myricxbio.com/
Total raised: $115.69M
Investors 1
| Date | Name | Website |
| 07.11.2023 | Brandon Ca... | brandoncap... |
Funding Rounds 1
| Date | Series | Amount | Investors |
| 11.07.2024 | Series A | $115.69M | - |
Mentions in press and media 17
| Date | Title | Description |
| 12.08.2026 | Silent Cancer Therapeutics Market Size to Reach USD 36.52 Billion by 2035, Driven by Precision Oncology and Advanced Cancer Therapies | Overview According to DataM Intelligence, the global silent cancer therapeutics market size was valued at USD 15.86 billion in 2025 and is forecast to reach USD 36.52 billion by 2035, expanding at a CAGR of 8.7% during 2026 to 2035. The mar... |
| 11.07.2026 | Global Headlines Roar: Trump's FIFA Move, Soaring Markets, and Geopolitical Shifts | President Trump executed an unprecedented FIFA intervention, overturning a World Cup red card for US striker Folarin Balogun. Prediction markets surged with billions in trading volume. Wall Street futures pointed to new highs post-holiday. ... |
| 06.07.2026 | CNBC Daily Open: Trump sees red, prediction markets score and NATO’s defensive | President Donald Trump thanks FIFA for overturning U.S. striker Folarin Balogun’s red card. A report suggests European body UEFA could challenge the red card suspension. Norway defeats Brazil, and England scores a victory against Mexico to ... |
| 06.07.2026 | Patent cliff fuels Novartis’ $1.5bn swoop for London biotech | Swiss pharmaceutical giant Novartis has agreed to buy London-based biotech Myricx Bio for up to $1.5bn (£1.1bn) as global drugmakers continue deploying billions into promising biotech firms ahead of an estimated $450bn wave of patent expiri... |
| 28.07.2025 | Brandon Capital: Fund Six Closed At Over A$439 Million | Brandon Capital, Australasia’s leading life sciences venture capital firm, has announced the final close of its sixth fund, the Brandon BioCatalyst Fund Six (BB6), totaling A$439 million. New investors in BB6 include the Western Australia G... |
| 21.10.2024 | Despite faltering VC funding in Europe, healthtech made a comeback in Q3 | European startup funding faltered in Q3 2024, with startups raising a total of $11.3 billion – down 35% compared to the same time last year according to Dealroom. However, total investment in European tech so far in 2024 totals $40.9 billio... |
| 16.10.2024 | UK Startups: A Resilient Landscape Amidst VC Funding Challenges | The UK startup scene is a vibrant tapestry, woven with ambition and innovation. Despite facing headwinds, it remains a beacon of opportunity. Recent reports reveal a significant drop in venture capital (VC) funding during the third quarter ... |
| 15.10.2024 | Even in Record Low Quarter, UK Startups Top Europe in VC Funding | Funding for UK startups dropped dramatically in the third quarter of 2024, according to recent figures, as founders feel the pressure to find new sources of investment. Venture capital funding for startups fell by 50% from the previous quar... |
| 12.07.2024 | Myricx Bio: Revolutionizing Cancer Treatment with Novel Payloads | Myricx Bio, a UK-based biotech company, has secured a whopping £90 million in Series A funding to develop a groundbreaking class of payloads for antibody-drug conjugates (ADCs). Led by Novo Holdings and Abingworth, this investment marks a s... |
| 11.07.2024 | Myricx Bio Raises £90 Million In Series A To Develop Pay Class For Antibody-Drug Conjugates | Life science investor Novo Holdings announced that it has co-led a £90 million ($114 million) Series A financing for Myricx Bio, the largest European biotech Series A funding this year. Myricx Bio is a UK biotech company focusing on the dis... |
Show more